EMA Authorised: Rexatilux (ranibizumab) — Intas Third Party Sales 2005 S.L.

View source ↗

Summary

Authorisation of Rexatilux (ranibizumab) by EMA for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Macular Degeneration

Drugs mentioned

• Rexatilux (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration. MAH: Intas Third Party Sales 2005 S.L.. Decision date: 19/06/2026